摘要
目的探讨前列地尔注射治疗重型病毒性肝炎的疗效和安全性。方法将62例重型病毒性肝炎患者随机分为观察组和对照组,每组患者各31例。对照组患者接受常规治疗,包括护肝、退黄和对症支持治疗;观察组患者在常规治疗基础上接受前列地尔10g/d,1次/d注射治疗,每15d为1个疗程,必要时连续用2个疗程。观察两组患者的疗效和不良反应。结果观察组肝脏总有效率显著高于对照组(χ2=4.351,P=0.037);观察组患者血清胆红素降低显著优于对照组(t=2.488,P=0.014),凝血因子Ⅱ活动度升高显著优于对照组(t=3.607,P=0.001),观察组肝肾综合征发生率显著低于对照组(χ2=5.599,P=0.018),差异均具有统计学意义。两组患者均未出现严重不良反应。结论前列地尔注射液是一种治疗重型病毒性肝炎的安全有效的药物,有望成为重型病毒性肝炎的一种有效治疗手段。
Objective To investigate the curative effects and safety of alprostadil injection in the treatment of severe viral hepatitis. Methods Total of 62 patients with severe viral hepatitis were divided into two groups, randomly as observation group and control group, with 31 cases in each group. Patients in the control group were subjected to routine therapeutic program including hepatinica, jaundice treating drugs as well as symptomatic and supportive treatment. Based on routine therapeutic program, patients in the observation group were given instillation of 10 g/d alprostadil injection. The course of treatment lasted 15 days and a second course was ordered if necessary. The therapeutic effects and adverse reactions were observed. Results The total effective rate of the observation group was higher than that of the control group （x2= 4.351, P = 0.037）. Compared with the control group, the total serum bilirubin of patients in the observation group dropped to a significantly lower level （t = 2.488, P = 0.014）, the blood coagulation factor II activity was significantly increased （t=3.607, P = 0.001）, and the incidence of hepatorenal syndrome was significantly lower （x2 = 5.599, P = 0.018）. No severe adverse reaction occurred in both groups of patients. Conclusions Alprostadil injection is a safe and effective drug for the treatment of severe viral hepatitis, which could be used as a potential therapeutic means to treat severe viral hepatitis.
出处
《中华实验和临床感染病杂志（电子版）》
CAS
2013年第2期83-85,共3页
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
